Biophor Diagnostics, Inc. Traditional Premarket Notification 510(k) Submission RapidFRET Oral Fluid Assay for Opiates

# 510(k) Summary for the RapidFRET Oral Fluid Assay for OPIATES

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92

The assigned 510(k) number is: k133642

# 807.92(a)(1): Contact Information

Name: Biophor Diagnostics, Inc. Address: 1201 Douglas Avenue Redwood City, CA 94063

Contact: Nathaniel G. Butlin, Ph.D. Phone: 650-367-4954 Fax: 650-364-4985

807.92(a)(2): Device Name, Common Name and Classification

RapidFRET Oral Fluid Assay for OPIATES (Enzyme Immunoassay for Opiates) RapidFRET Oral Fluid Calibrator Set (Clinical Toxicology Calibrator) RapidFRET Oral Fluid Control Set (Drug Mixture Control Materials)

<table><tr><td rowspan=1 colspan=1>Product</td><td rowspan=1 colspan=1>Code</td><td rowspan=1 colspan=1>Class</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>RapidFRET Oral Fluid Assay for OPIATES</td><td rowspan=1 colspan=1>DJG</td><td rowspan=1 colspan=1>|</td><td rowspan=1 colspan=1>862.3650</td><td rowspan=1 colspan=1>91- Toxicology</td></tr><tr><td rowspan=1 colspan=1>RapidFRET Oral Fluid Calibrator Set</td><td rowspan=1 colspan=1>DKB</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>862.3200</td><td rowspan=1 colspan=1>91 - Toxicology</td></tr><tr><td rowspan=1 colspan=1>RapidFRET Oral Fluid Control Set</td><td rowspan=1 colspan=1>DIF</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>862.3280</td><td rowspan=1 colspan=1>91 - Toxicology</td></tr></table>

# 807.92(a)(3): Identification of Legally Marketed Predicate Devices

Thermo Scientific CEDIA® Opiates OFT Assay (k101754).

# 807.92(a}(4): Assay Principle

The RapidFRET Oral Fluid Assay for OPlATES is an In Vitro Diagnostic competitive immunoassay used to detect opiates in human oral fluid. This is a ready-to-use homogenous system that involves energy transfer between an acceptor fluorophore labeled to an antibody and a donor fluorophore labeled to drug. The assay is based on competition between drug in the sample and drug labeled with the donor fluorophore for a fixed number of binding sites on the antibody reagent. When acceptor and donor fluorophores are brought into close proximity through a binding event, energy transfer occurs. The fluorescence resonance energy transfer (FRET) signal is measured at the wavelength of the acceptor fluorophore and is inversely proportional to the amount of drug in the sample. A Cutoff Calibrator is used to translate the sample measurement into a positive or negative result. Controls are used to establish and monitor precision and accuracy.

Biophor Diagnostics, Inc. Traditional Premarket Notification S10(k) Submission RapidFRET Oral Fluid Assay for Opiates

# Device Description

The RapidFRET Oral Fluid Assay for Opiates is provided in an all liquid, ready to use format. Two reagents are provided included a drug specific reagent and a second competitive donor reagent. The kit is provided with reagents and microtiter plates. A Cutoff Calibrator is used to translate the sample measurement into a positive or negative result. Controls are used to establish and monitor precision and accuracy. Calibrators and controls are sold separately.

# 807.92(a)(5): Intended Use

The RapidFRET Oral Fluid Assay for OPIATES is a homogeneous time-resolved fluorescence assay that is intended for prescription use in central laboratories only on the RapidFRET Integrated Workstation. The assay is used to perform a qualitative screen for Opiates at 40 ng/ml in neat oral fluid samples collected with the RapidEASE Oral Fluid Collector. This assay is calibrated against Morphine. This assay provides only a preliminary result. To obtain a confirmed analytical result, a more specific alternate chemical method such as GC/MS or LC/Ms/MS is required. Professional judgment should be applied to any drug test result, particularly when using preliminary positive results. For In Vitro Diagnostic Use Only.

The RapidFRET Oral Fluid Calibrator Set and RapidFRET Oral Fluid Control Set are intended for use only with the RapidFRET Oral Fluid Assay for OPIATES and samples collected with the RapidEASE Oral Fluid Collector. The cutoff calibrator is used to determine the cutoff level and translate the assay measurement into a positive or negative result. The positive and negative controls are used to monitor laboratory systems, operators, precision, accuracy and assay conditions. For In Vitro Diagnostic Use Only.

807.92(a)(6): Technological Similarities and Differences to the Predicate   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Candidate Device(RapidFRET OPIATES)</td><td rowspan=1 colspan=1>Predicate Device(Thermo Opiates, K101754)</td></tr><tr><td rowspan=1 colspan=1>Indications forUse</td><td rowspan=1 colspan=1>Qualitative determination of opiates inhuman oral fluid in central labs.Prescription use only.</td><td rowspan=1 colspan=1>- Qualitative determination of opiates inhuman oral fluid in clinical setting.</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Competitive homogeneousimmunoassay.</td><td rowspan=1 colspan=1>Competitive homogeneousimmunoassay.</td></tr><tr><td rowspan=1 colspan=1>KitComponents</td><td rowspan=1 colspan=1>1 Drug specific antibody reagent in liquid,ready to use format.1 Drug conjugate reagent in liquid, readyto use format.</td><td rowspan=1 colspan=1>1 Drug specific antibody reagent(marketed in combination as a lyophilizedreagent and reconstitution buffer).1 Drug conjugate reagent (marketed incombination as a lyophilized reagent andreconstitution buffer).</td></tr></table>

Biophor Diagnostics, Inc. Traditional Premarket Notification 510(k) Submission RapidFRET Oral Fluid Assay for Opiates   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Candidate Device(RapidFRET OPIATES)</td><td rowspan=1 colspan=1>Predicate Device(Thermo Opiates, K101754)</td></tr><tr><td rowspan=1 colspan=1>PerformanceCharacteristics</td><td rowspan=1 colspan=1>Precision, accuracy, crossreacting/interfering studies demonstrateequivalence to the predicate device.</td><td rowspan=1 colspan=1>Precision, accuracy, crossreacting/interfering studies are similar tothe RapidFRET Oral Fluid Assay forOPIATES.</td></tr><tr><td rowspan=1 colspan=1>Safety andEffectiveness</td><td rowspan=1 colspan=1>Demonstrated in bench testing anddescribed in Pl, equivalent to predicate.</td><td rowspan=1 colspan=1>Demonstrated in bench testing anddescribed in PI.</td></tr><tr><td rowspan=1 colspan=1>Neat Oral FluidCutoff Level</td><td rowspan=1 colspan=1>40 ng/mL neat oral fluid.</td><td rowspan=1 colspan=1>30 ng/mL neat oral fluid using a 10 ng/mlcutoff calibrator to account for sampledilution by collection device.</td></tr><tr><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>RapidFRET Integrated Workstationavailable exclusively from BiophorDiagnostics, Inc.</td><td rowspan=1 colspan=1>MGC240 analyzer</td></tr><tr><td rowspan=1 colspan=1>SampleCollection</td><td rowspan=1 colspan=1>Neat oral fluid is collected with theRapidEASE Oral Fluid Collector via directexpectoration. No diluent is used andsample is stored in glass sample tubewith inert screw cap.</td><td rowspan=1 colspan=1>Oral fluid is collected with the Oral-EzeSaliva Collection System. This device usesan absorbent swab and diluent. Sample isstored in plastic tube with snap cap.</td></tr><tr><td rowspan=1 colspan=1>Principle andProcedure</td><td rowspan=1 colspan=1>Drugs in the oral fluid sample competewith the drug conjugate donorfluorophore for a fixed number of bindingsites on the individual drug antibodyacceptor reagents. When acceptor anddonor fluorophores are brought intoclose proximity, through the bindingevent, fluorescent energy transfer ismeasured.The amount of drug in the specimensample is inversely proportional to theassay signal as measured by timeresolved fluorescence.</td><td rowspan=1 colspan=1>The assay is based on the sampleanalytes competing with analyteconjugates to one inactive fragment of β-galactosidase for antibody binding sites.The amount of drug in the specimen isdirectly proportional to the assay signalas measured by absorbance.</td></tr><tr><td rowspan=1 colspan=1>Controls andCalibratorLevels</td><td rowspan=1 colspan=1>Calibrators are available at O ng/mL and40 ng/mL. Controls are available at 20ng/mL and 60 ng/mL.</td><td rowspan=1 colspan=1>Calibrators are available at 0 ng/mL, 10ng/mL, and 80 ng/mL. Controls areavailable at additional levels.</td></tr></table>

# 807.92(b)(1): Brief Description of Study Data:

A series of studies were performed that evaluated the device performance characteristics including precision and analytical sensitivity, correlation with GC/MS and LC/MS/MS, cross reactivity, and analytical specificity that are summarized below.

# Precision and Analytical Sensitivity

Three lots of the RapidFRET Oral Fluid Assay for OPIATES were analyzed, four times daily, for a minimum of 20 days. Negative oral fluid pools were spiked with Morphine at $0 \%$ , $2 5 \%$ , $50 \%$ , $7 5 \%$ , $100 \%$ , $12 5 \%$ , $1 5 0 \%$ , $1 7 5 \%$ and $200 \%$ of the cutoff level corresponding to approximately 0, 10, 20, 30, 40, 50, 60, 70 and $8 0 n g / m L$ The aggregate data is summarized in the table below:

<table><tr><td rowspan=1 colspan=10>Table 18.2.7. All Lots Precision Results Summary by Data Points</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>175%</td><td rowspan=1 colspan=1>200%</td></tr><tr><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>185</td><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>263</td><td rowspan=1 colspan=1>294</td><td rowspan=1 colspan=1>278</td></tr><tr><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>263</td><td rowspan=1 colspan=1>294</td><td rowspan=1 colspan=1>278</td></tr></table>

Table 18.2.8. All Lots Precision Results Summary by Percent Agreement   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>75%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>125%</td><td rowspan=1 colspan=1>150%</td><td rowspan=1 colspan=1>175%</td><td rowspan=1 colspan=1>200%</td></tr><tr><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>66%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>34%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>263</td><td rowspan=1 colspan=1>294</td><td rowspan=1 colspan=1>278</td></tr></table>

The data indicate that the analytical sensitivity is between $7 5 \%$ and $12 5 \%$ of cutoff, and expected results were achieved at a $100 \%$ frequency.

# Correlation with MS Quantitation

Neat oral fluid was collected with the RapidEASE Oral Fluid Collection Device from volunteers potentially positive and negative for opiates. The samples $( n = 2 4 5 )$ were randomized and blinded to the instrument operator and assayed using RapidFRET Opiates reagents. Following screening, positive and negative samples were sent for confirmatory testing. The summarized data are shown below.

Table of Summary Results   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>NegativeAs determined by thepredicate device or lessthan half the cutoffconcentration byGC/MS</td><td rowspan=1 colspan=1>Near CutoffNegativeBetween 50%below the cutoffand the cutoffconcentration</td><td rowspan=1 colspan=1>Near CutoffPositiveBetween thecutoff and 50%above the cutoffconcentration</td><td rowspan=1 colspan=1>High PositiveGreater than50% above thecutoffconcentration</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>53</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>177</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Table of Discordant Results   

<table><tr><td rowspan=1 colspan=1>Cutoff Value</td><td rowspan=1 colspan=1>Assay(POS/NEG)</td><td rowspan=1 colspan=1>Drug / Metabolite LC/MS Value (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>40 ng/mL</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Total Opiates = 36.5 ng/mL (26.8 ng/mLMorphine and 9.7 ng/mL Codeine)</td></tr></table>

The data indicate that the RapidFRET Oral Fluid Assay for OPIATES had an agreement of $5 9 8 \%$ for RapidFRET positive samples and an agreement of $100 \%$ for RapidFRET negative samples in neat oral fluid samples collected with the RapidEASE Oral Fluid Collector.

# Cross Reactivity and Analytical Specificity

A compound library of 167 different structurally related and unrelated compounds including metabolites, OTC and prescription medications and drugs of abuse was used to evaluate the device cross reactivity and specificity. Compounds were spiked at $3 0 , 0 0 0 ~ \mathrm { n g / m L }$ into neat oral fluid pool aliquots with $0 \ : \mathrm { n g / m L }$ , $2 0 ~ \mathrm { { n g / m L } }$ and $6 0 ~ \mathsf { n g / m l }$ of morphine, processed with the RapidEASE Collector, and tested with the RapidFRET OPIATES assay. Those compounds that gave an unexpected result were further titrated to determine the concentration at which the cross-reacting compound yielded a result approximately equivalent to the cutoff. Twenty nine (29) structurally related compounds were determined to cross-react below $3 0 , 0 0 0 ~ \mathrm { { n g / m L } }$ in the absence of morphine with twelve cross-reacting at $1 0 0 0 ~ \mathrm { { n g / m L } }$ equivalence or less.

<table><tr><td colspan="5" rowspan="1">Table 18.8.2. Structurally Related Cross Reactants</td></tr><tr><td colspan="1" rowspan="1">Compound</td><td colspan="1" rowspan="1">Level(ng/mL)</td><td colspan="1" rowspan="1">0% Morphinet(0 ng/mL)</td><td colspan="1" rowspan="1">50% Morphinet(20 ng/mL)</td><td colspan="1" rowspan="1">150% Morphinet(60 ng/mL)</td></tr><tr><td colspan="4" rowspan="1"> a   Rc  l F ol /</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">6-Monoacetylmorphine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">36 [111%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Amitriptyline</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">12,854 [0.3%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">12,215 [0.3%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">2,017 [2.0%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">31 [129%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Cyclizine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">10,179 [0.4%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Cyclobenzaprine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">17,887 [0.2%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Desipramine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">6,754 [0.6%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Diacetylmorphine (Heroin)</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">40 [100%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Dihydrocodeine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">32 [125%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Doxepin</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">19,538 [0.2%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">d-Propoxyphene</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">23,593 [0.2%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Ethylmorphine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">31 [129%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Flurazepam</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">5,905 [0.7%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">41 [98%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Hydromorphone</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">35 [114%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Compound</td><td colspan="1" rowspan="1">Level(ng/mL)</td><td colspan="1" rowspan="1">0% Morphinet(0 ng/mL)</td><td colspan="1" rowspan="1">50% Morphine†{20 ng/mL}</td><td colspan="1" rowspan="1">150% Morphinet(60 ng/mL)</td></tr><tr><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">1,368 [2.9%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Levorphanol</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">348 [11%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">12,634 [0.3%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Morphine-3βDG</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">31 [129%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Nalorphine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">37 [108%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Naloxone</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">429 [9.3%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Naltrexone</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">2,720 [1.5%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Normorphine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">3,318 [1.2%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Oxycodone</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">533 [7.5%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">831 [4.8%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Rifampin</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">8,371[0.5%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">Thioridazine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">18,104 [0.2%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">*</td></tr><tr><td colspan="1" rowspan="1">Trimipramine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">1,947 (2.1%]</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td></tr></table>

t  p h RapiRET IATE enesu SEG $n \geq 1 m L$ of the cross-reactant that gives a Cutoff equivalent response. \*Due to high cross reactivity at $0 \pi \mathrm { g } / \mathsf { m L }$ morphine, a $6 0 n \times 8 / m L$ morphine spike was not analyzed.

A second study evaluated common substances such as foods and dental products as well as pH variations. HSA, ethanol, baking soda, whole blood, hemoglobin, hydrogen peroxide, sodium chloride, cholesterol, denture adhesive, ascorbic acid, bilirubin, IgA, IgG and IgM were spiked into neat oral fluid pool aliquots that contained either $2 0 n g / \mathsf { m L }$ or $6 0 ~ \mathrm { { n g / m l } }$ of morphine. Neat oral fluid pool was titrated to pH values of 5, 6, 7, 8 and 9, spiked with morphine to $2 0 ~ \mathrm { { n g / m l } }$ or $6 0 n g / m L$ and assayed with the RapidFRET OPIATES Assay. The effects of antiseptic mouthwash, cough syrup, cranberry juice, orange juice, tooth paste, chewing tobacco, cigarettes, chewing gum, hard candy, teeth whitening strips, cola, water, antacid, coffee and tea were evaluated by asking volunteers to use a specific item and provide an oral fluid sample. These samples were then spiked with morphine to $2 0 n \mathrm { g / m L }$ or $6 0 ~ \mathsf { n g / m l } .$ , processed with a RapidEASE Collector and assayed with the RapidFRET OPIATES device. All compounds at the listed concentrations gave a NEG result when spiked with 20 $\mathsf { n g / m l }$ morphine and a POS result when spike with $6 0 n g / m L$ morphine.

# 807.92(b)(3): Conclusions

The RapidFRET Oral Fluid Assay for OPIATES including the RapidFRET Oral Fluid Negative and Cutoff Calibrators, the RapidFRET Oral Fluid Negative and Positive Controls and the RapidEASE Oral Fluid Collector were determined to be substantially equivalent in safety and effectiveness for their intended use.

January 24, 2014

BIOPHOR DIAGNOSTICS, INC. NATHANIEL BUTLIN VICE PRESIDENT 1201 DOUGLAS AVE REDWOOD CITY CA 94063

Re: K133642 Trade/Device Name: RapidFRET Oral Fluid Assay For Opiates RapidFRET Oral Fluid Calibrator Set RapidFRET Oral Fluid Control Set Regulation Number: 21 CFR 862.3650 Regulation Name: Opiate test system Regulatory Class: II Product Code: DJG, DKB, DIF Dated: November 26, 2013 Received: November 27, 2013

Dear Mr. Butlin:

We have reviewed your Section 5 10(k) premarket notification of intent to market the device referenced above and have determined the devic is ubstantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate coerce prir to May 28, 196, the enactment date f the Medical Device mendments,  to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and CosmetiAct (Act) that do ot require approval o a premarket approval application (MA). You may, therefore, market the device, subject to the general controls provisions of the Act. The l n ois c et at s devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above)into either class II (Special Controls) or class III (MA), it may be subject to additional controls. Existing major regulations affecting your device can be ound in heCode  Federal Regulations, Tite , Parts 800 to In addition, FA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with allthe Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the

electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809) please contact the Division of Small Manuacturers. International and Consumer   
Assistance at its toll-free numiber (800) 638 2041 or (301) 796-7100 or at its Internet address http://wwv.fda.gov/MedicalDevices/ResourcesforYou/lndustry/defauilt.htm.Also, please note the regulation entitled, "Misbranding by reference to premarket notification” (21CFR Par 0.9For questions gari the eporting ver eventsunder the DR egulatn CFR Part 803). please go to   
http://www.fda.gov/MedicalDeviccs/Safety/ReportaProblem/default.htm for the CDRH's Office ofSurveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/lndustry/default.him.

Sincerely yours.

# Courtney H. Lias -S

Courtney H. Lias. Ph.D. .   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

apiRET Oral Fluid Assay or OPIATES; RapidFRET Oral Fluid Calibrator Set; RapidRET Oral Fluid Control Set

Indications for Use (Describe)

o i Opiates at $4 0 n g / m L$ in neat oral fluid samples colleced with the RapidEAE Oral Fluid Collector.This assay is calibrated aainst using preliminary positive results. For In Vitro Diagnostic Use Only.

nor boratory stes,perators, precisn, accuracy nd assy conditions.For nVio DagnostUs.